SLC6A3 and major depressive disorder: This included inhibitors used in the treatment of depression (imipramine and atomoxetine) and attention-deficit hyperactivity disorder (atomoxetine), a smoking cessation agent (bupropion), a psychostimulant drug (cocaine), and pharmacological tool compounds with selectivity for NET (nisoxetine and talopram) or DAT (GBR 12,909, JHW 007 and rimcazole).